Spartalizumab for sarcoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 17 Mar 2021: Trial registered, NCT04802876
  2. 12 Apr 2021: Trial started, NCT04802876

The trials

NCT04802876: Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

State
Under way
Phase
Phase 2
People
184 planned
Started
12 Apr 2021
Primary completion
30 Sep 2025
Arms
Spartalizumab (PDR001) (Cohort-1 PD1-high), Spartalizumab (PDR001) (Cohort-2 PD1-low)
Results
None posted
  1. 17 Mar 2021: Trial registered
  2. 12 Apr 2021: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.